Germantown, MD – December 10, 2025 – Barinthus Biotherapeutics announced new results from the Phase 1 AVALON clinical trial evaluating VTP-1000, its investigational antigen-specific immune tolerance therapy for celiac disease, confirming dose-dependent pharmacological activity and a favorable safety profile with no treatment-related serious adverse events (SAEs) in the single ascending dose (SAD) portion of the study. The multi-ascending dose (MAD) phase, which incorporates a controlled gluten challenge, is now underway and is expected to deliver key readouts in the second half of 2026.
Science Significance
The early results highlight meaningful scientific progress in immune tolerance induction, a frontier approach aimed at halting autoimmune reactions at their root cause. VTP-1000 is engineered using Barinthus Bio’s SNAP-TI nanoparticle platform, which co-delivers gluten-derived peptide antigens and the immunomodulator rapamycin to promote targeted immune reprogramming.
The SAD cohort demonstrated robust IL-2 responses without triggering systemic inflammation, a key indicator that the candidate initiates immune recognition while avoiding harmful activation. These findings suggest that VTP-1000 could meaningfully alter the pathological gluten-triggered cascade in celiac disease, offering a new paradigm in antigen-specific tolerance therapies.
Regulatory Significance
The Phase 1 AVALON trial represents a major step toward regulatory evaluation of the first disease-modifying therapy for celiac disease, a condition with no approved treatments. By demonstrating clean safety outcomes and dose-dependent immune activity, Barinthus Bio has established the foundational evidence required for future Phase 2 dose-optimization studies and eventual regulatory engagement for late-stage development. The incorporation of a gluten challenge in the MAD arm is especially important, as regulators will expect demonstration that pharmacological effects translate into meaningful modulation of gluten-induced immune activation under controlled exposure. Ongoing data collection will also inform the company’s long-term CMC and immunogenicity-risk strategies as the therapy advances through the development pipeline.
Advertisement
Business Significance
The update reinforces Barinthus Bio’s position as a clinical-stage leader in antigen-specific immunology, advancing a high-value asset in an underserved market affecting nearly 80 million people globally. VTP-1000 sits at the forefront of the company’s I&I portfolio, powered by the differentiated SNAP-TI platform, which has potential applications across multiple autoimmune diseases. Positive early clinical data strengthens Barinthus Bio’s competitive standing and supports continued investor confidence in the company’s development strategy, pipeline prioritization, and partnership potential. As the AVALON trial progresses, Barinthus Bio moves closer to delivering a therapy that could reshape the commercial landscape for gluten-triggered autoimmune disorders.
Patients’ Significance
For patients living with celiac disease, the implications of VTP-1000 are profound. Today, management relies solely on strict lifelong gluten avoidance, a difficult and imperfect strategy due to the ubiquitous presence of gluten and risks of cross-contamination. Even trace exposure can cause vomiting, diarrhea, intestinal inflammation, and malabsorption, resulting in long-term complications and reduced quality of life. The Phase 1 findings suggest that a single dose of VTP-1000 may prime the immune system toward tolerance, potentially reducing adverse responses to gluten exposure. If confirmed in future stages, this could allow patients to live more confidently and safely, with reduced disease burden and fewer lifestyle limitations.
Policy Significance
The AVALON trial aligns with broader health-policy priorities emphasizing innovative treatments for autoimmune diseases, especially those with large patient populations but no approved therapeutics. Demonstrating a path to immune reprogramming without systemic immunosuppression supports emerging regulatory and reimbursement frameworks that prioritize precision-guided, disease-modifying therapies. As celiac disease is widely underdiagnosed despite its prevalence, advances like VTP-1000 could prompt renewed policymaker attention to screening strategies, early detection, and investment in autoimmune research infrastructure. The development of antigen-specific tolerance therapies may also influence future guidelines on dietary management and risk mitigation for chronic autoimmune conditions.
Barinthus Bio’s Phase 1 AVALON trial update marks a pivotal achievement in the pursuit of immune tolerance therapies for celiac disease, demonstrating early pharmacologic promise and strong tolerability for VTP-1000. With the ongoing MAD portion set to explore clinical effects under gluten challenge, the company is positioned to advance the first potential disease-modifying treatment for a condition affecting millions worldwide. As the science matures, VTP-1000 could help redefine how autoimmune diseases are approached—shifting care from lifelong avoidance strategies to durable immune recalibration.
Source: Barinthus Biotherapeutics press release
